What went through my head when I read the PR "T
Post# of 30028
(Total Views: 337)
Posted On: 02/01/2022 10:18:38 PM
What went through my head when I read the PR
"TLVR2 consists of a formulation that includes NLC-EXT-2 and NLC-EXT-1, a newly isolated compound first identified in January 2021 as part of raw material qualification experiments that was confirmed in April 2021 to have significantly more potent 3CL protease inhibitor than NLC-EXT-2. NLC-EXT-2 has a 3CL protease ICD50 binding affinity of 20mM vs. NLC-EXT-1 that has a 3CL protease ICD50 binding affinity of 0.8mM."
What was used in the observational trial which results were announced September 30, 2021?
https://www.globenewswire.com/news-release/20...lovir.html
In Phase II..
Part I enrolled patients from December 2020 through February 2021 primarily during the Third COVID Wave (Alpha and Beta variants).
Part II enrolled patients from May 2021 through November 2021 primarily during the Fourth COVID Wave (Delta variant).
Observational trial must have been using TLVR1
But why did it work?
Was the virus not as bad at that point in time?
Did those patients also have redesiver or does redesiver actually screw up a less potent version of Tollovir?
I'm no whiz kid but there seems to be a huge difference between 0.8mM and 20mM. That is 25x difference.
"The binding affinity is the strength of the interaction between two (or more than two) molecules that bind reversibly (interact)."
In any case, where else can you get a version of a drug that is used in trials that worked in Phase II and people are sharing their stories now of how it kept them out of the hospital.
This is going to be fun ride while JP is still on his plastic skate board with wooded wheels trying to keep up.
"TLVR2 consists of a formulation that includes NLC-EXT-2 and NLC-EXT-1, a newly isolated compound first identified in January 2021 as part of raw material qualification experiments that was confirmed in April 2021 to have significantly more potent 3CL protease inhibitor than NLC-EXT-2. NLC-EXT-2 has a 3CL protease ICD50 binding affinity of 20mM vs. NLC-EXT-1 that has a 3CL protease ICD50 binding affinity of 0.8mM."
What was used in the observational trial which results were announced September 30, 2021?
https://www.globenewswire.com/news-release/20...lovir.html
In Phase II..
Part I enrolled patients from December 2020 through February 2021 primarily during the Third COVID Wave (Alpha and Beta variants).
Part II enrolled patients from May 2021 through November 2021 primarily during the Fourth COVID Wave (Delta variant).
Observational trial must have been using TLVR1
But why did it work?
Was the virus not as bad at that point in time?
Did those patients also have redesiver or does redesiver actually screw up a less potent version of Tollovir?
I'm no whiz kid but there seems to be a huge difference between 0.8mM and 20mM. That is 25x difference.
"The binding affinity is the strength of the interaction between two (or more than two) molecules that bind reversibly (interact)."
In any case, where else can you get a version of a drug that is used in trials that worked in Phase II and people are sharing their stories now of how it kept them out of the hospital.
This is going to be fun ride while JP is still on his plastic skate board with wooded wheels trying to keep up.
(1)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼